Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedEL
EQT Life Sciences
Activity from announced rounds
Activity in this selectionOct 11, 2026 · Europe · Jan 1, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $401.2M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedNeurent Medical
Neurent Medical develops NEUROMARK, a minimally invasive radiofrequency treatment for chronic rhinitis.
€62.5MSeries C
Role not disclosedExciva
Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease
€51MSeries B
Role not disclosed